de Graeff PA - Search Results

1

Impact of safety-related regulatory action on clinical practice: a systematic review.

Piening S, Haaijer-Ruskamp FM, de Vries JT, van der Elst ME, de Graeff PA, Straus SM, Mol PG. Piening S, et al. Among authors: de vries jt, de graeff pa. Drug Saf. 2012 May 1;35(5):373-85. doi: 10.2165/11599100-000000000-00000. Drug Saf. 2012. PMID: 22480319 Review.

2

A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.

Mol PG, Straus SM, Piening S, de Vries JT, de Graeff PA, Haaijer-Ruskamp FM. Mol PG, et al. Among authors: de vries jt, de graeff pa. Drug Saf. 2010 Jun 1;33(6):463-74. doi: 10.2165/11532840-000000000-00000. Drug Saf. 2010. PMID: 20486729

3

Additional safety risk to exceptionally approved drugs in Europe?

Arnardottir AH, Haaijer-Ruskamp FM, Straus SM, Eichler HG, de Graeff PA, Mol PG. Arnardottir AH, et al. Among authors: de graeff pa. Br J Clin Pharmacol. 2011 Sep;72(3):490-9. doi: 10.1111/j.1365-2125.2011.03995.x. Br J Clin Pharmacol. 2011. PMID: 21501215 Free PMC article.

4

Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment Reports.

Arnardottir AH, Haaijer-Ruskamp FM, Straus SM, de Graeff PA, Mol PG. Arnardottir AH, et al. Among authors: de graeff pa. Drug Saf. 2011 Nov 1;34(11):1101-14. doi: 10.2165/11592060-000000000-00000. Drug Saf. 2011. PMID: 21981437

5

Healthcare professionals' self-reported experiences and preferences related to direct healthcare professional communications: a survey conducted in the Netherlands.

Piening S, Haaijer-Ruskamp FM, de Graeff PA, Straus SM, Mol PG. Piening S, et al. Among authors: de graeff pa. Drug Saf. 2012 Nov 1;35(11):1061-72. doi: 10.1007/BF03261992. Drug Saf. 2012. PMID: 23061782

6

The Additional Value of an E-Mail to Inform Healthcare Professionals of a Drug Safety Issue: A Randomized Controlled Trial in the Netherlands.

Piening S, de Graeff PA, Straus SM, Haaijer-Ruskamp FM, Mol PG. Piening S, et al. Among authors: de graeff pa. Drug Saf. 2013 Sep;36(9):723-31. doi: 10.1007/s40264-013-0079-x. Drug Saf. 2013. PMID: 23797603 Clinical Trial.

7

Post-approval safety issues with innovative drugs: a European cohort study.

Mol PG, Arnardottir AH, Motola D, Vrijlandt PJ, Duijnhoven RG, Haaijer-Ruskamp FM, de Graeff PA, Denig P, Straus SM. Mol PG, et al. Among authors: de graeff pa. Drug Saf. 2013 Nov;36(11):1105-15. doi: 10.1007/s40264-013-0094-y. Drug Saf. 2013. PMID: 24048690

8

Impact of safety-related regulatory action on drug use in ambulatory care in the Netherlands.

Piening S, Reber KC, Wieringa JE, Straus SM, de Graeff PA, Haaijer-Ruskamp FM, Mol PG. Piening S, et al. Among authors: de graeff pa. Clin Pharmacol Ther. 2012 May;91(5):838-45. doi: 10.1038/clpt.2011.308. Clin Pharmacol Ther. 2012. PMID: 22472991

9

When direct health-care professional communications have an impact on inappropriate and unsafe use of medicines.

Reber KC, Piening S, Wieringa JE, Straus SM, Raine JM, de Graeff PA, Haaijer-Ruskamp FM, Mol PG. Reber KC, et al. Among authors: de graeff pa. Clin Pharmacol Ther. 2013 Apr;93(4):360-5. doi: 10.1038/clpt.2012.262. Epub 2012 Dec 27. Clin Pharmacol Ther. 2013. PMID: 23443752

10

Perceived barriers for treatment of chronic heart failure in general practice; are they affecting performance?

Kasje WN, Denig P, de Graeff PA, Haaijer-Ruskamp FM. Kasje WN, et al. Among authors: de graeff pa. BMC Fam Pract. 2005 May 3;6(1):19. doi: 10.1186/1471-2296-6-19. BMC Fam Pract. 2005. PMID: 15869704 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

128 results

Search Page

Filters